Logos Global Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Logos Global Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.9M	Sell	125,000 -325,000	-72%	-$29.4M	0.6%	44
2026 Q1	$39.1M	Buy	450,000 +260,000	+137%	+$25.3M	1.95%	14
2025 Q4	$20.3M	Sell	190,000 -10,000	-5%	-$1.06M	1.23%	28
2025 Q3	$20.2M	Buy	200,000 +70,000	+54%	+$6.5M	1.81%	23
2025 Q2	$8.21M	Buy	+130,000	New	+$7.96M	0.91%	35
2023 Q4	–	Sell	-400,000	Closed	-$9.17M	–	67
2023 Q3	$9.17M	Buy	+400,000	New	+$8.96M	1.22%	27

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Logos Global Management's RYTM Position: Q2 2026 in Review

Logos Global Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 72% in Q2 2026, selling an estimated $29.4M and leaving 125,000 shares worth $13.9M. The position accounts for 0.6% of the portfolio, ranked #44.

Logos Global Management first reported a position in RYTM in Q3 2023 and has held it in 6 quarters since. The position peaked at $39.1M in Q1 2026. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Logos Global Management held 125,000 shares of Rhythm Pharmaceuticals worth $13.9M as of Q2 2026.
Logos Global Management sold 325,000 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $29.4M.
Rhythm Pharmaceuticals made up 0.6% of Logos Global Management's portfolio in Q2 2026, its #44 holding.
Logos Global Management first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
Logos Global Management's Rhythm Pharmaceuticals position peaked at $39.1M in Q1 2026.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.